Cervilenz Boosts Series A to $8.35M


Cleveland-based Cervilenz has added to its Series A round, closing the round with $8.35 million. The company, backed by investors including Arboretum Ventures and Chrysalis Ventures, plans to use the funding to continue commercialization of its medical devices for women. The device is designed to predict the risk of preterm birth in pregnant women.

Find new deal opportunities, super-charge your fundraising efforts and track top managers with VCJ. Get your FREE trial! Or subscribe now

Sign up to our Newsletter

Receive updates from our PE HUB Wire and Top Stories of the Week newsletters:

We will not send you spam, and we don't share your email address with 3rd parties.